ISU Abxis Co., Ltd.

Quick facts

Marketed products

• Cerezyme® · Rare genetic disease / Lysosomal storage disorder
  Cerezyme is an enzyme replacement therapy that provides the missing glucocerebrosidase enzyme to break down glucocerebroside in patients with Gaucher disease.

Phase 3 pipeline

• Fabagal® (Agalsidase beta) · Rare genetic disease / Lysosomal storage disorder
  Agalsidase beta is a recombinant human enzyme that replaces deficient α-galactosidase A, breaking down accumulated globotriaosylceramide (Gb3) in cells.

Phase 1 pipeline

• Abcertin · Other
• EU-sourced Cerezyme
• ISU104

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• ISU Abxis Co., Ltd. portfolio CI brief
• ISU Abxis Co., Ltd. pipeline updates RSS